Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a once-daily pill help children with fatty liver disease?

NCT ID NCT07763015

Not yet recruiting Disease control Sponsor: Madrigal Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests an experimental oral drug called resmetirom in children aged 6 to 17 with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. The study aims to evaluate the drug's safety, how the body processes it, and its effects on the liver. Participants will take resmetirom once daily for about 14 days at different dose levels to help determine appropriate dosing for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
resmetirom (an oral drug taken once daily)
What this could lead to
If successful, this could help determine safe and effective dosing of resmetirom for children with MASH, potentially slowing or reversing liver damage.
What could go wrong
This is an early-phase study with a small number of participants, so results may not apply to all children. The drug may cause side effects or may not show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis liver disorder metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Riley Hospital for Children at IU Health

    Indianapolis, Indiana, 46402, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.